Neoadjuvant intraarterial chemotherapy for stage IIB-IIIB cervical cancer in Japanese women

  • Authors:
    • Shoji Kaku
    • Kentaro Takahashi
    • Yoshitaka Murakami
    • Shirou Wakinoue
    • Tetsuya Nakagawa
    • Yoshihiko Shimizu
    • Nobuyuki Kita
    • Yoichi Noda
    • Takashi Murakami
  • View Affiliations

  • Published online on: July 1, 2010     https://doi.org/10.3892/etm_00000102
  • Pages: 651-655
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Chemoradiotherapy is currently the main treatment for locally advanced cervical cancer, but neoadjuvant intraarterial chemotherapy (IA-NAC) has been reported to achieve favorable results. This study investigated the efficacy of several different IA-NAC regimens. The subjects were 55 patients with stage IIB-IIIB cervical cancer who received IA-NAC between January 1991 and April 2006. IA-NAC was administered for a total of 1-3 courses at 3-week intervals, with three different regimens being employed in chronological order. The response rate achieved with IA-NAC was 90.2% for squamous cell carcinoma, 60% for adenosquamous carcinoma and 42.9% for adenocarcinoma. Surgery was performed after IA-NAC in 36 patients, and radiotherapy alone was performed in 19 patients. The 5-year survival rate was 72.9% for patients with squamous cell carcinoma and 50% for those with adenocarcinoma or adenosquamous carcinoma. PAMF therapy (cisplatin, epirubicin, mitomycin-C and 5-fluorouracil) achieved a response rate of ≥90% for squamous cell carcinoma, as did CDDP + THP therapy (cisplatin plus pirarubicin), while PACF therapy (cisplatin, epirubicin, cyclophosphamide and 5-flurouracil) achieved a better response rate for adenosquamous carcinoma and adenocarcinoma. Grade 3 or 4 hematological toxicity was significantly more common with PAMF therapy. In conclusion, IA-NAC improved the survival of patients with squamous cell carcinoma. CDDP + THP therapy achieved a high response rate with little hematologic toxicity. PACF therapy achieved a significantly higher response rate in patients with adenosquamous carcinoma or adenocarcinoma. Therefore, IA-NAC may be a therapeutic option for locally advanced cervical cancer, particularly using the above-mentioned regimens.
View Figures
View References

Related Articles

Journal Cover

July-August 2010
Volume 1 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kaku S, Takahashi K, Murakami Y, Wakinoue S, Nakagawa T, Shimizu Y, Kita N, Noda Y and Murakami T: Neoadjuvant intraarterial chemotherapy for stage IIB-IIIB cervical cancer in Japanese women . Exp Ther Med 1: 651-655, 2010.
APA
Kaku, S., Takahashi, K., Murakami, Y., Wakinoue, S., Nakagawa, T., Shimizu, Y. ... Murakami, T. (2010). Neoadjuvant intraarterial chemotherapy for stage IIB-IIIB cervical cancer in Japanese women . Experimental and Therapeutic Medicine, 1, 651-655. https://doi.org/10.3892/etm_00000102
MLA
Kaku, S., Takahashi, K., Murakami, Y., Wakinoue, S., Nakagawa, T., Shimizu, Y., Kita, N., Noda, Y., Murakami, T."Neoadjuvant intraarterial chemotherapy for stage IIB-IIIB cervical cancer in Japanese women ". Experimental and Therapeutic Medicine 1.4 (2010): 651-655.
Chicago
Kaku, S., Takahashi, K., Murakami, Y., Wakinoue, S., Nakagawa, T., Shimizu, Y., Kita, N., Noda, Y., Murakami, T."Neoadjuvant intraarterial chemotherapy for stage IIB-IIIB cervical cancer in Japanese women ". Experimental and Therapeutic Medicine 1, no. 4 (2010): 651-655. https://doi.org/10.3892/etm_00000102